The complete clinical framework for oral appliance therapy — how mandibular advancement devices eliminate airway obstruction, who qualifies, what the evidence shows against CPAP, what happens when you refer a patient to DEEPdormir, and how long-term co-management works. Everything you need to speak about OAT with clinical confidence.
Lessons 3.1–3.4 build your clinical foundation for OAT. Lesson 3.5 walks you through what happens after you refer. Lesson 3.6 defines your ongoing co-management role.
The biomechanical mechanism of mandibular advancement — how protrusion of the mandible increases the posterior airway space, reduces airway collapsibility, and activates the genioglossus muscle to prevent obstruction. Includes a walkthrough of the titration process and how efficacy is measured post-fitting.
The clinical, anatomical, and situational factors that make a patient a strong OAT candidate — including OSA severity, dental prerequisites, jaw range of motion, TMJ status, and prior CPAP experience. Equal coverage of contraindications: who should not receive OAT and why.
A balanced, evidence-based comparison of the two primary OSA treatments. CPAP efficacy advantage per titration study vs. real-world outcomes when compliance is factored in. Why 5-year OAT compliance of ~80% vs. CPAP's ~50% often makes OAT the clinically superior choice for your patients.
The landmark randomized controlled trials supporting OAT. The AASM 2015 clinical practice guideline, AADSM treatment protocols, and the insurance and medical justification framework built around them. What "FDA-cleared" and "AASM-endorsed" mean in a clinical and billing context.
A complete walkthrough of the DEEPdormir treatment process — from the initial consultation through impressions, appliance fabrication, fitting, and titration. What your patients will experience after you refer them, so you can prepare them accurately and build confidence in the referral pathway.
Post-treatment follow-up schedules, efficacy verification via repeat testing, the signs of OAT success and failure, managing side effects (TMJ discomfort, tooth movement, occlusal changes), and when to escalate back to a sleep medicine physician. The co-management role your practice plays long-term.
This section covers the core clinical context for Module 3. Full depth is in the individual lessons.
A mandibular advancement device (MAD) is a custom-fitted oral appliance worn during sleep that holds the lower jaw (mandible) in a slightly forward, protruded position. This simple mechanical action produces a cascade of airway changes that eliminate or substantially reduce obstructive events.
The device advances the mandible anteriorly by a calibrated distance — typically 50–75% of maximum protrusive range, arrived at through a titration process. Upper and lower trays are connected by a mechanism that maintains this advancement position throughout the night.
Mandibular advancement stretches the soft tissue floor of the mouth and anterior pharyngeal walls, directly increasing the anteroposterior and lateral dimensions of the posterior airway. The velopharynx and retropalatal spaces — the primary sites of obstruction in OSA — are widened.
Protrusion of the mandible passively advances the genioglossus muscle — the primary tongue protrusor — reducing tongue prolapse into the posterior airway during sleep. This addresses the most common single anatomical contributor to OSA in most patients.
The combination of increased airway space and reduced muscle load on the posterior pharyngeal walls lowers the critical closing pressure (Pcrit) of the airway — the pressure at which the airway collapses. In OAT responders, Pcrit falls below the threshold that causes apnea events during normal sleep.
Both treatments are effective. The clinical question is not which works better per se — it is which produces better outcomes for the patient in front of you, accounting for adherence, tolerance, and quality of life. The evidence increasingly supports OAT as the real-world superior choice for a broad patient population.
When you refer a patient to DEEPdormir, this is the clinical journey they enter. Understanding this process in detail lets you prepare your patients accurately and answer every question they ask before, during, and after the referral.
The patient meets with a DEEPdormir sleep medicine physician for an intake consultation — either in-person at one of our 7 Long Island locations or via telehealth. The physician reviews the referring practice's STOP-BANG screening data, home sleep test results, and medical history. Treatment options are presented and discussed. If OAT is appropriate and elected, the patient proceeds to the dental evaluation.
A full dental evaluation confirms OAT candidacy — periodontal health, dentition adequacy, jaw range of motion, and TMJ status. Bite registration and upper/lower impressions (or digital scans) are taken. The maximum protrusive range is measured and an initial treatment position is calculated — typically 50–60% of maximum protrusion as a starting point.
The custom oral appliance is fabricated by a certified dental laboratory using the impressions and bite registration. Most appliances are returned within 2–3 weeks. The appliance is designed for precise anterior advancement with incremental titration capability — allowing the treating clinician to advance in small increments to the therapeutic position.
The patient returns for appliance delivery. Fit and retention are verified, insertion and removal are practiced until the patient is comfortable, and the appliance is set to the initial treatment position. Detailed care instructions are provided. The patient is instructed to return within 2–4 weeks for the first titration check.
Over 2–4 follow-up appointments, the appliance is advanced incrementally until the patient reports adequate symptom resolution or objective testing confirms adequate AHI reduction. Titration typically involves 0.25–0.5 mm advancements per visit. TMJ comfort and occlusal changes are monitored at every visit.
Once the therapeutic position is established, a follow-up home sleep test confirms objective AHI reduction. If successful, the patient moves to a long-term maintenance schedule (typically 6-month check-ins). The referring dental practice is a key co-management partner at every recall appointment — monitoring for occlusal changes, appliance wear, and any emerging TMJ concerns. This co-management role is covered in Lesson 3.6.
The American Academy of Sleep Medicine’s 2015 guideline established oral appliance therapy as a first-line treatment for mild-to-moderate OSA in adult patients who prefer OAT to CPAP, or for whom CPAP is not effective or tolerated. For severe OSA, CPAP is the preferred treatment; OAT is recommended as an alternative when CPAP is not tolerated or declined.
The American Academy of Dental Sleep Medicine’s treatment protocol establishes standards for evaluation, appliance selection, titration, follow-up, and co-management between the treating dentist and the supervising sleep medicine physician. It mandates objective efficacy testing (repeat sleep study) after titration reaches the therapeutic position.
Oral appliances for the treatment of OSA are Class II medical devices that require 510(k) clearance from the FDA. FDA clearance confirms that the device meets safety and efficacy standards equivalent to a predicate device already on the market. All appliances used by DEEPdormir hold current FDA clearance for OSA treatment.
Because OSA is a medical diagnosis and oral appliance therapy is prescribed by a physician, OAT bills as a medical benefit — not a dental benefit. This distinction is critical: most dental plans do not cover OAT, but most major medical plans do. Medicare covers OAT when the patient has a documented OSA diagnosis and meets clinical criteria. Full billing detail is in Module 6.
Your team should know these numbers. Your patients will ask.
After completing the lessons, you should be able to answer all of these before advancing to Module 4.
Describe the biomechanical mechanism by which a mandibular advancement device eliminates airway obstruction. What specific anatomical changes does protrusion produce?
Name three clinical criteria that make a patient a strong OAT candidate and two contraindications that would exclude or delay treatment with an oral appliance.
What does the 2015 AASM Clinical Practice Guideline say about OAT for mild-to-moderate OSA? When does it recommend OAT for severe OSA?
Why does real-world OAT efficacy often match or exceed CPAP despite CPAP showing higher per-hour AHI reduction in titration studies? What is the key data point that explains this?
Walk through the six steps of the DEEPdormir OAT process from initial consultation to efficacy verification. Approximately how long does the full process take?
A patient asks: “Is this FDA-approved?” What is the accurate answer and how do you explain the distinction between FDA clearance and FDA approval in plain language?
Ready to continue?
Proceed to Module 4 — TMJ & the Airway Connection